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Objective: Approximately one-quarter of military personnel who deployed to combat stations sustained one or more blast-related, closed-head injuries. Blast injuries result from
the detonation of an explosive device.The mechanisms associated with blast exposure that
give rise to traumatic brain injury (TBI), and place military personnel at high risk for chronic
symptoms of post-concussive disorder (PCD), post-traumatic stress disorder (PTSD), and
depression are not elucidated.
Methods:To investigate the mechanisms of persistent blast-related symptoms, we examined expression profiles of transcripts across the genome to determine the role of gene
activity in chronic symptoms following blast-TBI. Active duty military personnel with (1) a
medical record of a blast-TBI that occurred during deployment (n = 19) were compared to
control participants without TBI (n = 17). Controls were matched to cases on demographic
factors including age, gender, and race, and also in diagnoses of sleep disturbance, and
symptoms of PTSD and depression. Due to the high number of PCD symptoms in the
TBI+ group, we did not match on this variable. Using expression profiles of transcripts
in microarray platform in peripheral samples of whole blood, significantly differentially
expressed gene lists were generated. Statistical threshold is based on criteria of 1.5 magnitude fold-change (up or down) and p-values with multiple test correction (false discovery
rate <0.05).
Results:There were 34 transcripts in 29 genes that were differentially regulated in blast-TBI
participants compared to controls. Up-regulated genes included epithelial cell transforming sequence and zinc finger proteins, which are necessary for astrocyte differentiation
following injury. Tensin-1, which has been implicated in neuronal recovery in pre-clinical TBI
models, was down-regulated in blast-TBI participants. Protein ubiquitination genes, such as
epidermal growth factor receptor, were also down-regulated and identified as the central
regulators in the gene network determined by interaction pathway analysis.
Conclusion: In this study, we identified a gene-expression pathway of delayed neuronal
recovery in military personnel a blast-TBI and chronic symptoms. Future work is needed to
determine if therapeutic agents that regulate these pathways may provide novel treatments
for chronic blast-TBI-related symptoms.
Keywords: traumatic brain injury, military, post-concussive disorder, gene-expression

Abbreviations: ANOVA, analysis of variance; BMI, body-mass index; DSM-IV,
diagnostic and statistical manual of mental disorders, 4th ed; EGFR, epidermal
growth factor receptor; FDR, false discovery rate; IPA, interactive pathway analysis; MARCH8, membrane-associated ring finger (C3HC4) 8, E3 ubiquitin protein
ligase; NSI, neurobehavioral symptom inventory; OSA, obstructive sleep apnea;
PCD, post-concussive disorder; PCL-M, PTSD checklist military version; PTEN,
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phosphatase and tensin homolog; PTSD, post-traumatic stress disorder; QIDS, quick
inventory of depressive symptomatology; SCID, structured clinical interview for
DSM-III-R; SF-36, short form (36) health survey; TBI, traumatic brain injury; TNS1,
tensin-1; VEGF, vascular endothelial growth factor; WARCAT, warrior administered
retrospective casualty assessment tool; ZC3H12C, zinc finger CCCH-type
containing 12C.
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INTRODUCTION
Improvised explosive devices (IEDs) have induced blast traumatic
brain injuries (TBI) in approximately one-quarter of military
personnel deployed to combat stations in Operations Enduring
Freedom and Iraqi Freedom (1). In addition to the blast wave, blast
events often involve a blunt-force component, placing individuals
at risk for alterations in consciousness, disruptions in memory,
and headaches from both mechanisms of the blast-TBI (2, 3).
Following deployment these military personnel are at high risk
for on-going neurological and psychological symptoms, including
post-concussive disorder (PCD), post-traumatic stress disorder
(PTSD), and depression (4, 5). Our understanding of a complete and precise mechanism of blast-related pathology is limited,
resulting in an inability to determine military personnel at risk for
these chronic disorders, and to inform interventions to mitigate
these risks.
Clinical studies report differential gene expression following
TBI; however, these studies do not include blast-TBI, and most
use post-mortem, neuronal tissue samples obtained from severe
TBI patients (6–10). Studies that use imaging techniques report
cortical thinning in the left superior temporal and frontal gyri
(11) and altered neurocircuitry (12) in military personnel with a
history of blast-TBI and chronic symptoms. These current studies are limited because they could neither examine the biological
processes that contributed to neuronal compromise nor did they
determine the impact of other variables that may affect gene
expression or morphology of the brain, including comorbid PTSD,
depression, and chronic pain. These considerations are essential,
as not-determining the impact of these complexities can result in
an inability to determine what the consequences are from the blast
itself (13). Although there are advantages of pre-clinical models of blast, there are also challenges in translating findings that
include differential injury mechanisms in the laboratory, limiting
application to clinical patients including military personnel (14).
Although pre-clinical models are not in agreement in the preferential models of blast-TBI, there is definitive evidence linking
blast-TBIs to neuronal function changes (15). Blast-TBIs result
in cerebral edema and vasospasm, which contribute to global
acute neuronal compromise through an influx of immune cells
and inflammatory processes (16, 17). Within 24 h of blast-TBI, an
up-regulation of glial fibrillary acidic protein, vimentin, and complement component 1 is observed (18), as well as an activation of
microglia (19), which are key to TBI recovery as they propagate
inflammation to neighboring neurons, providing vital protection. In traditional TBI, microglia communicates with peripheral
immune cells to modulate immune activities (20). Specifically,
microglia interacts with peripheral immune cells, resulting in a
gene-expression signature in the peripheral blood cells that may
be informative of central recovery activities (21). This assertion has
been recently supported in a pre-clinical study that reports similar
micro-RNA changes in the cerebral spinal fluid and serum following a blast, suggesting that peripheral samples provide insights
into neuronal changes following blast (22).
Therefore, we suggest that central neuronal recovery mechanisms may be detected in the periphery through whole blood samples obtained from military personnel with a history of blast-TBI
who are seeking care for chronic symptoms. To further investigate
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this postulation, we enrolled military personnel with medically
documented blast-TBI, as well as controls without TBI. Instruments and a clinical evaluation were undertaken to determine current symptoms of PCD, PTSD, depression, and sleep disturbance.
Differentially expressed genes related to blast-TBI were obtained
by comparing military personnel with blast-TBI to matched controls without TBI using a whole-genome approach that eliminates any biased selection of biological targets. We addressed the
possible impact of PTSD, depression, and sleep disturbance on
gene-expression through group matching, on diagnoses of sleep
disturbance, and symptom severity of PTSD and depression. This
approach may provide a minimally invasive opportunity to investigate the gene-expression pathways that contribute to blast-TBI
pathology in military personnel. We expect this line of research
to ultimately inform pharmacological agents to better treat military personnel with chronic symptoms and deficits following a
blast-TBI.

MATERIALS AND METHODS
CLINICAL METHODS

This study was an observational assessment of U.S. military
personnel at the Madigan Army Medical Center who had
been deployed within the previous 18 months. Exclusion criteria
included (1) no history of drug or alcohol abuse in the previous
year and (2) no current medical condition that required substantial treatments (cancer, diabetes, HIV, autoimmune disorders), or
a severe psychiatric condition (i.e., schizophrenia or bipolar disorder). Subjects with neurological disorders other than headaches,
e.g., multiple sclerosis, seizure disorders, and a history of stroke,
were excluded. Subjects with blast-TBI were identified by having
a blast-TBI documented in their medical record. Blast-TBI cases
did not require a pre-specified severity of PCD symptoms. Controls neither have a medical history of any TBI in their records
nor report a TBI when asked. Controls were matched to blastcases as much as possible on critical variables that would have
influenced gene-expression including the following: age, gender,
race/ethnicity, and diagnoses of sleep disorder, and symptom
severity of PTSD and depression. The medical record was used
to determine the number and type of prescribed medications that
military personnel were prescribed. This study was approved by
the institutional review board at the Madigan Army Medical Center, and informed consent was obtained from each individual prior
to any baseline measurements.
Determination of TBI

The case history of TBI was extracted from medical records of
the 117 military personnel enrolled in a larger observational
study. Clinical information obtained includes the following: type
of injury, diagnosis of TBI that includes severity, loss of consciousness, and time since the TBI. To be a blast-TBI case, the
participant must also have reported sustaining a TBI through
administration of the warrior administered retrospective casualty
assessment tool (WARCAT) (23). A negative response to the WARCAT was necessary to be in the control group. This tool obtains
data on possible war-related TBI injuries and post-deployment
injuries, and whether they were injured from mechanisms commonly associated with TBI while deployed, whether any injuries
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resulted in an altered mental status indicative of TBI, and/or
whether specific somatic and neuropsychiatric symptoms commonly associated with mild TBI occurred after the injury (immediately post-injury and/or post-deployment). The somatic and
neuropsychiatric symptoms were not used to make the diagnosis
of TBI. The diagnosis of mild TBI was made in accordance with
American Congress of Rehabilitation Medicine mild TBI criteria,
which requires an injury event followed by a loss of consciousness
or alteration of mental state and was consistent with criteria for
TBI delineated by the Department of Defense and Department of
Veterans Affairs.
Determination of PCD, PTSD, and depression symptoms

The neurobehavioral symptom inventory (NSI) was used to measure PCD symptom severity. The NSI is a 22-item measure
designed to evaluate self-reported post-concussion symptoms
(e.g., headache, balance, nausea, etc.). The NSI requires the test
taker to rate the presence/severity of each symptom on a 5-point
scale (none, mild, moderate, severe, very severe). A total score is
obtained by summing the ratings for the 22 items (range = 0–88).
The NSI has a high-internal consistency (total alpha = 0.95; subscale alpha = 0.88–0.92) and reliability (r = 0.88–0.93) (24). This
instrument was administered to all participants.
Symptoms of PTSD were assessed by the PTSD checklist military version (PCL-M), resulting in a score between 0 and 80,
with higher numbers indicating the greatest severity (25). The
quick inventory of depressive symptomatology (QIDS) was used
to measure total symptoms of depression, resulting in a score of
0–27 (26). Chronic pain was evaluated by the bodily pain score
from the short form (36) health survey (SF-36). We used this in
conjunction with the medical record to determine a diagnosis of
pain, by either a score lower than 70 for military personnel with a
pain diagnosis in their electronic medical record or a low-bodily
pain subscale score (<30) on the SF-36 (27).
LABORATORY METHODS

RNA sample preparation

Blood samples were collected in PAXgene blood RNA tubes and
processed with PAXgene™ Blood RNA Kits (PreAnalytiX, Qiagen)
for RNA extraction according to the manufacturer’s instruction.
Quality and quantity of extracted RNA were evaluated with the
NanoDrop DN-1000 spectrophotometer (Thermo Fisher Scientific, Wilmington, DE, USA) and the Agilent Bioanalyzer 2100
eukaryotic total RNA Nano assay (Agilent Technologies, Inc., Santa
Clara, CA, USA). The 260/280 ratio ranged 2.03–2.34 and the RNA
integrity numbers (RIN) were >7.0 in all samples.
Microarray gene-expression profiling

Purified RNAs (100 ng) were amplified, fluorescently labeled, and
hybridized to Affymetrix GeneChip Human Gene U133 Plus 2.0
Arrays (Affymetrix, Inc., Santa Clara, CA, USA), which contain more than 54,000 probes representing thousands of specific
gene coding regions. After thorough washing, the raw data were
obtained by laser scanning imaging. All RNA preparation and transcriptome assays were undertaken in the NINR laboratory based
on manufacturer’s protocols.
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Data analysis

Descriptive statistics for all demographic and clinical variables
were calculated using SPSS Statistics (IBM SPSS Inc., Chicago,
IL, USA) (Tables 1 and 2). Comparisons were made between
the groups using t -tests. A priori p-values <0.05 were considered
significant.
Microarray data were analyzed for a total of 36 participants
for gene-expression profiles using Partek Genomics Suite software
(Partek Inc., St. Louis, MO, USA). The probe-level robust multichip average background correction, quantile normalization, log2
transformation, and probe-set summarization were performed on
gene-expression intensity values. Multi-way analysis of variance
(ANOVA) mixed models were constructed for differential expressions for both the blast-TBI + PCD (N = 19) and control (N = 17)
groups. Since samples were processed on different dates, batch correction was applied. Pair-wise comparisons were made by setting
the contrast between blast-TBI and control groups. Significant
differentially expressed gene lists were generated based on criteria of 1.5 magnitude fold-change (up or down), and p-values
corrected for false discovery rate (FDR < 0.05) using the step-up
Benjamini–Hochberg method.
Interactive pathway analysis (IPA) (Qiagen Ingenuity Systems, Redwood City, CA, USA) was performed on differentially
expressed genes to identify gene interactions and networks associated with biological functions.
Clinical variables were compared using ANOVA models
for continuous variables, and chi-square for categorical data.
Although our data were small in sample size, it met the assumptions of the tests we used, including ANOVA. Bonferroni corrections were used to adjust for multiple comparisons.

RESULTS
DEMOGRAPHIC AND CLINICAL CHARACTERISTICS

The demographic and clinical characteristics of the 36 participants used in this analysis are described in Table 1. The blast-TBI
group (N = 19) was group matched to a control group (N = 17)
to ensure that the groups did not differ on any demographic [age,
body-mass index (BMI), gender, race, and military rank] or clinical
characteristics (depression, and PTSD symptom severity and sleep
diagnoses). There was no difference in the total number of military
personnel taking any prescribed medication, or the type of medications, the most common being serotonin reuptake inhibitors
(SSRIs), anti-hypertensive, and prazosin. The mean ages of the
blast-TBI and control groups were 32.0 and 30.9 years, respectively.
The sample was male, primarily Caucasian, and demonstrated high
rates of comorbid symptoms of sleep disorders, depression, and
PTSD. The blast-TBI group reported a far greater severity of PCD
symptoms compared to controls.
All 19 participants in the TBI group experienced a blast injury,
and 84.25% had a loss of consciousness following the blast-TBI.
By medical diagnosis in theater, approximately 78.95% had a mild
blast-TBI, and 21.05% of the sample was diagnosed with a moderate blast-TBI. In this sample, a brain contusion was reported to
have occurred at the time of the blast in 36.84% of the sample,
and all were determined to be mild in severity. More than half of
the sample had more than one blast-TBI (52.6%), and approximately one-third had (38.8%) three or more blast-TBIs. The time

October 2014 | Volume 5 | Article 198 | 3

Heinzelmann et al.

Differential gene expression in blast-TBI/PCD

Table 1 | Demographics and clinical characteristics for blast-TBI + PCD (N = 19) and control (N = 17) groups.
TBI + PCD (N = 19)

Control (N = 17)

Mean age in years (SD)

32.00 (9.04)

30.94 (7.48)

F 1,35 = 0.14, p = 0.72

Mean BMI (SD)

29.30 (3.76)

31.65 (4.82)

F 1,35 = 2.03, p = 0.16

Gender, % (No)

N/A
100.0% (19)

100.0% (17)

Caucasian

73.8% (14)

58.8% (10)

Mixed

15.8% (3)

11.8% (2)

All other

10.4% (2)

19.4% (5)

Male

χ2 = 4.22, p = 0.52

Race, % (No)

χ2 = 0.97, p = 0.62

Rank, % (No)
Lower enlisted

57.9% (11)

58.8% (10)

Senior NCO

36.8% (7)

35.3% (6)

5.2% (1)

5.9% (1)

OSA

10.5% (2)

5.9% (1)

Insomnia

31.6% (8)

23.5% (4)

OSA + insomnia

31.5% (6)

58.8% (10)

None

15.8% (3)

11.8% (2)

Officer

χ2 = 2.79, p = 0.43

Sleep diagnoses, % (No)

Depression severity (QIDS)
PTSD severity (PCL-M)
Prescribed medications, % yes (no)
SSRI

Significance

9.6 (5.1)

8.7 (4.8)

32.05 (18.8)

29.90 (15.1)

36.8% (6)

41.2% (7)

15.8% (3)

11.8% (2)

Prazosin

21.1% (4)

17.6% (3)

Anti-hypertensive

15.8% (3)

23.5% (4)

F 1,35 = 2.42, p = 0.10
F 1,35 = 2.31, p = 0.14
χ2 = 1.51, p = 0.51

TBI, traumatic brain injury; PCD, post-concussive disorder; SD, standard deviation; no, number; NCO, non-commissioned officer; BMI, body-mass index; OSA, obstructive sleep apnea; QIDS, quick inventory of depressive symptomatology; PTSD, post-traumatic stress disorder; PCL-M, PTSD checklist military version; SSRI, selective
serotonin reuptake inhibitor.

since TBI varied, with 3–6 months, 6–12 months, and more than
12 months having elapsed for 15.8, 31.6, and 52.7% of the group,
respectively.
The breakdown of the 22 components of the NSI for both the
blast group and control group are shown in Table 2. Scores on 17
of the 22 components were significantly different between the two
groups, based on a p-value of 0.05, and adjustment for multiple
comparisons.
DIFFERENTIAL GENE EXPRESSION IN TBI

Differential expression of transcripts between blast-TBI and control groups resulted in multiple down-regulated (Table 3) and
up-regulated genes (Table 4). Notable down-regulated genes are
membrane-associated ring finger (C3HC4) 8, E3 ubiquitin protein ligase (MARCH8, −1.6123 fold-change), tensin-1 (TNS1,
−2.368 fold-change), tripartite motif containing 58 (TRIM58,
−1.918), Kruppel-like factor 1 (KLF1, −1.766), WNK lysine deficient protein kinase 1 (WNK1, −1.630), ankyrin1 (ANK1, −1.628),
and epidermal growth factor receptor (EGFR, −1.526). Differentially expressed gene pathways are shown in the network figure
(Figure 1), generated from the ingenuity knowledge database.
Figure 1 indicates that the majority of the genes relate to ubiquitin
C (UBC), and that EGFR is related to multiple gene-networks.
Sub-group analyses

We separated subjects with moderate TBI from mild, and also did a
subsequent analysis on TBIs within the last 12 months compared to
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subjects with a TBI more than 12 months ago. Lastly, we grouped
subjects by multiple blast-TBIs, compared to subjects with only
one blast-TBI. None of these analyses yielded a significant finding over the 1.5-fold-threshold, with the adjustment for multiple
comparisons.

DISCUSSION
To our knowledge this is the first study to report differential gene
expression in the peripheral blood of military personnel with a
history of blast-TBI during deployment compared to matched
controls. Here, we report that differential expression of genes
involved in the secondary injury processes may contribute to the
long-term symptoms of PCD that are common among this group.
These findings are significant because the genes we report to be
differentially expressed are related to neuronal recovery following
TBI, suggesting for the first time that a peripheral sample of blood
may be used to better understand central processes in a sample of
military personnel who have chronic blast-TBI related symptoms.
Specifically, our finding of a reduction in the membraneassociated ring finger (C3HC4) 8, E3 ubiquitin protein ligase
(MARCH8) as well as tripartite motif containing 58 (TRIM58)
in military personnel with blast-TBI suggest that adequate functionality of the ubiquitin proteasome is essential for recovery from
blast-TBI. Protein ubiquitination protects neurons from the detrimental impact of accumulating reactive oxygen, nitrogen species,
and free release of zinc initiates (28) by initiating the removal of
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Table 2 | Neurobehavioral symptom inventory for blast-TBI + PCD
(N = 19 and control (N = 17) groups.
TBI + PCD

Control

(N = 19)

(N = 17)

Significance

Forgetfulness

3.19 (0.75)

1.71 (1.16)

F1,35 = 18.72, p < 0.001

Concentration

2.69 (0.70)

1.29 (1.16)

F1,35 = 17.13, p < 0.001

Slowed thinking

2.37 (0.89)

1.06 (1.30)

F1,35 = 11.44, p = 0.002

Dizziness

1.19 (0.83)

0.41 (0.51)

F1,35 = 10.56, p = 0.003

Headache

2.31 (1.08)

1.12 (1.05)

F1,35 = 10.36, p = 0.003

Hearing problems

2.06 (1.18)

0.88 (1.22)

F1,35 = 7.96, p = 0.008

Sleep difficulty

3.37 (0.72)

2.59 (0.87)

F1,35 = 7.96, p = 0.008

Nausea

0.94 (1.06)

0.18 (0.39)

F1,35 = 7.63, p = 0.010

Decision making

2.25 (1.07)

1.24 (1.15)

F1,35 = 6.91, p = 0.013

Irritability

2.81 (0.66)

1.88 (1.32)

F1,35 = 6.46, p = 0.016

Balance

1.19 (0.91)

0.53 (0.62)

F1,35 = 5.93, p = 0.021

Numbness

2.06 (1.57)

0.82 (1.38)

F1,35 = 5.82, p = 0.022

Coordination

1.38 (0.81)

0.65 (0.93)

F1,35 = 5.73, p = 0.023

Frustration

2.44 (0.96)

1.53 (1.23)

F1,35 = 5.52, p = 0.025

Light sensitivity

1.31 (1.08)

0.59 (0.87)

F1,35 = 4.54, p = 0.041

Taste/smell changes

0.81 (0.98)

0.18 (0.73)

F1,35 = 4.51, p = 0.042

Noise sensitivity

1.50 (1.21)

0.65 (1.12)

F1,35 = 4.44, p = 0.043

Vision problems

1.31 (1.14)

0.59 (0.94)

F 1,35 = 3.99, p = 0.054

Anxiety

2.75 (1.24)

1.82 (1.51)

F 1,35 = 3.69, p = 0.064

Depression

2.00 (1.03)

1.35 (1.27)

F 1,35 = 2.55, p = 0.120

Appetite changes

1.56 (1.32)

0.88 (1.22)

F 1,35 = 2.38, p = 0.133

Fatigue

2.75 (1.00)

2.47 (2.50)

F 1,35 = 0.17, p = 0.680

TBI, traumatic brain injury; PCD, post-concussive disorder.
Italic font: significant group difference. NSI scale ranges from 0 to 4 for each item,
with a 0 indicating that the symptom is not present.

oxidized or misfolded proteins that result following injury (18).
In fact, higher concentrations of the protein encoded by UBCterminal hydrolase-L1 is one of the primary proteomic biomarkers
of acute TBI (29–31), with high concentrations being related to the
onset of chronic symptoms in pediatric patients (30).
Pre-clinical models link blast-TBIs to the activation of the
autonomous nervous system and the neuroendocrine–immune
system, suggesting that neuronal pathology results from the
over-activation of multiple biological systems (32). For example, blast-TBIs result in increases in inflammatory cytokines and
chemokines, as well as orexin A, and neuropilin-2 release (33).
Pre-clinical models also link blast to an increase in UCH-L1 in
blood and CSF, with CSF elevations lasting for 14 days, as well as
increases in other putative biomarkers of brain injury glial fibrillary acid protein, and neuron-specific enolase (34). Minimization of the ubiquitin pathway following a blast-TBI, by inducing
hypothermic conditions, resulted in less UCH-L1 activity following blunt force and a reduction of neuronal and glial damage (35).
Therefore, additional studies are needed to determine how the
ubiquitin pathway relates to neuronal damage following blast, and
if it may be a pharmacological target to promote neuronal recovery
from blast.
Therefore, reduction in the expression of this gene suggests
that this process is down-regulated and may contribute to chronic
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neurological symptoms and impairments in military personnel
with a blast-TBI. This assertion is further supported by pre-clinical
models that link down-regulation in protein ubiquitination genes
to poor neuronal repair (36), greater neuronal loss (37, 38), and
less neurodegeneration (39). A previous study has linked increased
zinc accumulations to reduced function of the ubiquitin pathway
in cultured neurons (40). Additional studies that include acute
biomarkers and determine changes in gene-expression over time
are needed to determine the role of protein ubiquitination in blastTBI recovery, as this line of research may inform pharmacological
agents to promote recovery.
We also report reduced expression of TNS1, a gene that is
pivotal to neuronal recovery following a TBI, which works in coordination with protein ubiquitination genes. Thus, our finding of a
reduction in TNS1 in conjunction with reductions in protein ubiquitination genes leads us to question if a down-regulation in these
genes may compromise neuronal recovery following blast-TBI,
resulting in chronic neurological symptoms and deficits. Increases
in the activity of TNS1 are linked to a risk for the onset of cancer and allergy induced asthma (41, 42). In a recent study, TBIs
have been associated with an increased risk for brain cancer (43),
suggesting that this TNS1 activity may increase morbidity risks
following TBI. Therefore, additional studies are needed to validate
our finding and to determine how TNS1 may relate to blast-TBI
and chronic neurological symptoms.
Axonal injury and degeneration, whether primary or secondary,
contribute to the morbidity and mortality risks following TBI,
which is shaped in part by the EGFR pathway through the activation of astrocytes. Astrocytes promote neuronal survival through
potentiation of collateral synapses, migration of neuronal progenitor cells, and differentiation of glial progenitor cells following
TBI (44, 45). EGFR is also a peripheral precursor for vascular
endothelial growth factor (VEGF), which plays a role in angiogenesis and has been shown to be neuroprotective following TBI
in pre-clinical models (46–48). Thus, EGFR is similar to protein
ubiquitination, down-regulation, and may occur following blastTBI, and place military personnel at greater risk for poor neuronal
repair and insufficient regeneration, resulting in the development
of chronic symptoms and deficits. Future studies that utilize biomarkers collected sooner following the blast-TBI in larger and
more representative samples may determine this relationship.
Although many of the genes that were significantly different
in the blast-TBI group compared to controls related to neuronal
compromise, a number of genes were not. One such gene was
up-regulation of MLF1 interacting protein, a gene that suppresses
cancer cell progression (49), as well the gene for outer dense fiber
of sperm tails 2-like (ODF2L), which relates to defective spermatozoa (50). In addition, we also did not observe alterations in genes
linked to blast-TBI in pre-clinical models, including inflammation (33), and putative biomarkers of brain injury, including glial
fibrillary acid protein and neuron-specific enolase (34). It may
be that since many participants in our sample population had a
TBI that occurred over a year prior to enrollment, other nonrelated processes may have occurred, possibly contributing to the
identification of non-expected candidates.
Our findings are limited by the cross-sectional nature of
the study in a relatively small sample of military personnel.
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Table 3 | Significantly down-regulated genes comparing blast-TBI + PCD (N = 19) to control (N = 17) groups.
Probe-set ID

Gene symbol

Gene title

p-Value

Fold-change

221748

TNS1

Tensin-1

0.00062

−2.3682

215047

TRIM58

Tripartite motif containing 58

0.00012

−1.9188

210504

KLF1

Kruppel-like factor 1 (erythroid)

0.00094

−1.7663

221246

TNS1

Tensin-1

0.00061

−1.6963

228770

GPR146///LOC100505551///

G protein-coupled receptor 146///uncharacterized

0.00029

−1.684

LOC100505568

LOC100505551///uncharacterized LOC
0.0001

−1.6534

221824

8-Mar

Membrane-associated ring finger (C3HC4) 8, E3 ubiquitin
protein ligase

201912

GSPT1

G1 to S phase transition 1

0.00057

−1.6369

212430

RBM38

RNA binding motif protein 38

0.00092

−1.6368

1555068

WNK1

WNK lysine deficient protein kinase 1

0.00017

−1.6307

218863

TNS1

Tensin-1

0.00066

−1.6286

205389

ANK1

Ankyrin 1, erythrocytic

0.00088

−1.6284

224690

FAM210B

Family with sequence similarity 210, member B

0.00054

−1.6254

224789

DCAF12

DDB1 and CUL4 associated factor 12

0.00019

−1.618

202242

TSPAN7

Tetraspanin 7

0.00015

−1.6131

231933

March8

Membrane-associated ring finger (C3HC4) 8, E3 ubiquitin

0.00065

−1.6123

protein ligase
224693

FAM210B

Family with sequence similarity 210, member B

0.0008

−1.6016

227935

PCGF5

Polycomb group ring finger 5

0.00077

−1.5973

207801

RNF10

Ring finger protein 10

0.00057

−1.5533

217736

EIF2AK1

Eukaryotic translation initiation factor 2-alpha kinase 1

0.00035

−1.5522

202974

MPP1

Membrane protein, palmitoylated 1, 55 kDa

0.00079

−1.5427

221958

WLS

Wntless homolog (Drosophila)

0.00085

−1.5417

225167

FRMD4A

FERM domain containing 4A

0.00037

−1.5352

1565484

EGFR

Epidermal growth factor receptor

8.01E-06

−1.5261

201285

MKRN1

Makorin ring finger protein 1

0.00033

−1.5139

225168

FRMD4A

FERM domain containing 4A

0.00065

−1.5086

1565483

EGFR

Epidermal growth factor receptor

4.11E-07

−1.5053

235993

PSMF1

Proteasome (prosome, macropain) inhibitor subunit 1 (PI31)

0.00026

−1.505

Microarray differentially expressed genes between groups that passed FDR (5%).
TBI, traumatic brain injury; FDR, false discovery rate.

Additional larger studies are required to confirm our findings.
Additionally, our design did not allow for randomization. To
combat this limitation, we matched controls to blast-TBI participants on diagnoses of sleep disturbance and symptom severity
of PTSD and depression. Although this allowed for isolation of
gene expression changes more related to blast-TBI, the heterogeneity of symptoms of PCD and times since the blast event
were issues that we were not able to address with the current
design. In addition, without a third comparison group with a TBI
not related to blast, we are unable to be certain that our findings are related to blast-TBI. We were limited in not including
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a clinician administered diagnostic tool to determine diagnoses
of PTSD and depression, which is an issue in this group of
patients who often present with complex symptoms that may be
psychosomatic in nature. We report high rates of comorbidity
in PCD, PTSD, and depression symptoms, as well as perceived
health declines (51), and greater psychosomatic illness severity
(52). Future larger studies that allow for comparison of differing symptom profiles of PCD and other comorbid symptoms will
provide insights into both the shared and unique gene-expression
pathways that underlie complex clinical presentations following
blast-TBI.
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Table 4 | Significantly up-regulated genes comparing blast-TBI + PCD (N = 19) to control (N = 17) groups.
Probe-set ID

Gene symbol

Gene title

p-Value

Fold-change

242539

DIS3L2

DIS3 mitotic control homolog (S. cerevisiae)-like 2

0.000341

1.7507

219787

ECT2

Epithelial cell transforming sequence 2 oncogene

0.000281

1.6386

218883

MLF1IP

MLF1 interacting protein

8.53E-05

1.6065

1553696

ZNF569

Zinc finger protein 569

0.000737

1.5581

228859

C4orf21

Chromosome 4 open reading frame 21

0.000252

1.5335

231909

ODF2L

Outer dense fiber of sperm tails 2-like

0.000284

1.5258

231899

ZC3H12C

Zinc finger CCCH-type containing 12C

0.000174

1.5192

219174

IFT74

Intraflagellar transport 74 homolog (Chlamydomonas)

0.000763

1.5179

230165

SGOL2

Shugoshin-like 2 (S. pombe)

1.47E-05

1.5107

Microarray differentially expressed genes between groups that passed FDR (5%).
TBI, traumatic brain injury; FDR, false discovery rate.

FIGURE 1 | Generated molecular network based on differential
expression between traumatic brain injury (TBI) and control groups
using ingenuity knowledge database. Coloring is based on the
expression values of the genes (fold changes shown), down-regulation
in green and, up-regulation in red. Genes with no coloring are added

www.frontiersin.org

from ingenuity knowledge database. Direct and indirect relationships
are shown by solid and dashed lines, respectively. The arrow indicates
specific directionality of interactions. Genes with an asterisk indicate
that multiple identifiers (probe-sets) map to the gene in the molecular
network.
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Taken together, the identification of down-regulation in protein
ubiquitination and mediation of this pathway in gene expression, as well as down-regulation of EGFR and TNS1, suggest
involvement of these gene-expression pathways in chronic TBI
pathology. Both of these gene-pathways protect neurons from secondary injuries following TBI and are highly specific to neurons
(53, 54), and suggest that secondary injury or repair cascades can
be detected in a peripheral sample of blood from military personnel with blast-related injuries even when injuries are not acute.
Future studies are necessary to determine how variation in these
gene-expression pathways may contribute to the heterogeneity in
recovery from blast-TBI, as well as how manipulation of these
pathways through the administration of pharmacological agents
may promote recovery.

ACKNOWLEDGMENTS
This study was funded, in part, by the Center for Neuroscience and
Regenerative Medicine (Grant 60855).

REFERENCES
1. Owens BD, Kragh JF Jr, Wenke JC, Macaitis J, Wade CE, Holcomb JB. Combat
wounds in operation Iraqi freedom and operation enduring freedom. J Trauma
(2008) 64(2):295–9. doi:10.1097/TA.0b013e318163b875
2. DePalma RG, Burris DG, Champion HR, Hodgson MJ. Blast injuries. N Engl
J Med (2005) 352(13):1335–42. doi:10.1056/NEJMra042083
3. Warden DL, French LM, Shupenko L, Fargus J, Riedy G, Erickson ME, et al. Case
report of a soldier with primary blast brain injury. Neuroimage (2009) 47(Suppl
2):T152–3. doi:10.1016/j.neuroimage.2009.01.060
4. Seelig AD, Jacobson IG, Smith B, Hooper TI, Boyko EJ, Gackstetter GD, et al.
Sleep patterns before, during, and after deployment to Iraq and Afghanistan.
Sleep (2010) 33(12):1615–22.
5. Tsai JC. Neurological and neurobehavioral sequelae of obstructive sleep apnea.
Neurorehabilitation (2010) 26(1):85–94. doi:10.3233/NRE-2010-0538
6. Zhou YW, Zhang YG, Deng WN. [A primary study on the ARP-SRP gene expression profiling of brain injury by cDNA microarray]. Fa Yi Xue Za Zhi (2002)
18(3):146–9. doi:10.1529/biophysj.106.100776
7. Michael DB, Byers DM, Irwin LN. Gene expression following traumatic brain
injury in humans: analysis by microarray. J Clin Neurosci (2005) 12(3):284–90.
doi:10.1016/j.jocn.2004.11.003
8. Kukacka J,Vajtr D, Huska D, Prusa R, Houstava L, Samal F, et al. Blood metallothionein, neuron specific enolase, and protein S100B in patients with traumatic
brain injury. Neuro Endocrinol Lett (2006) 27(Suppl 2):116–20.
9. Frugier T, Crombie D, Conquest A, Tjhong F, Taylor C, Kulkarni T, et al. Modulation of LPA receptor expression in the human brain following neurotrauma.
Cell Mol Neurobiol (2011) 31(4):569–77. doi:10.1007/s10571-011-9650-0
10. Frugier T, Conquest A, McLean C, Currie P, Moses D, Goldshmit Y. Expression
and activation of EphA4 in the human brain after traumatic injury. J Neuropathol
Exp Neurol (2012) 71(3):242–50. doi:10.1097/NEN.0b013e3182496149
11. Tate DF, York GE, Reid MW, Cooper DB, Jones L, Robin DA, et al. Preliminary
findings of cortical thickness abnormalities in blast injured service members and
their relationship to clinical findings. Brain Imaging Behav (2014) 8(1):102–9.
doi:10.1007/s11682-013-9257-9
12. Yeh PH, Wang B, Oakes TR, French LM, Pan H, Graner J, et al. Postconcussional
disorder and PTSD symptoms of military-related traumatic brain injury associated with compromised neurocircuitry. Hum Brain Mapp (2014) 35(6):2652–73.
doi:10.1002/hbm.22358
13. Rosenfeld JV, McFarlane AC, Bragge P, Armonda RA, Grimes JB, Ling GS. Blastrelated traumatic brain injury. Lancet Neurol (2013) 12(9):882–93. doi:10.1016/
S1474-4422(13)70161-3
14. Panzer MB, Wood GW, Bass CR. Scaling in neurotrauma: how do we apply
animal experiments to people? Exp Neurol (2014) 261C:120–6. doi:10.1016/j.
expneurol.2014.07.002
15. Effgen GB, Vogel EW III, Lynch KA, Lobel A, Hue CD, Meaney DF, et al.
Isolated primary blast alters neuronal function with minimal cell death in

Frontiers in Neurology | Neurotrauma

Differential gene expression in blast-TBI/PCD

organotypic hippocampal slice cultures. J Neurotrauma (2014) 31(13):1202–10.
doi:10.1089/neu.2013.3227
16. Ling G, Bandak F, Armonda R, Grant G, Ecklund J. Explosive blast neurotrauma.
J Neurotrauma (2009) 26(6):815–25. doi:10.1089/neu.2007.0484
17. Cho HJ, Sajja VS, Vandevord PJ, Lee YW. Blast induces oxidative stress, inflammation, neuronal loss and subsequent short-term memory impairment in rats.
Neuroscience (2013) 253:9–20. doi:10.1016/j.neuroscience.2013.08.037
18. Kochanek PM, Dixon CE, Shellington DK, Shin SS, Bayır H, Jackson EK, et al.
Screening of biochemical and molecular mechanisms of secondary injury and
repair in the brain after experimental blast-induced traumatic brain injury in
rats. J Neurotrauma (2013) 30(11):920–37. doi:10.1089/neu.2013.2862
19. Readnower RD, Chavko M, Adeeb S, Conroy MD, Pauly JR, McCarron RM,
et al. Increase in blood-brain barrier permeability, oxidative stress, and activated
microglia in a rat model of blast-induced traumatic brain injury. J Neurosci Res
(2010) 88(16):3530–9. doi:10.1002/jnr.22510
20. Hernandez-Ontiveros DG, Tajiri N, Acosta S, Giunta B, Tan J, Borlongan CV.
Microglia activation as a biomarker for traumatic brain injury. Front Neurol
(2013) 4:30. doi:10.3389/fneur.2013.00030
21. Woodcock T, Morganti-Kossmann MC. The role of markers of inflammation in
traumatic brain injury. Front Neurol (2013) 4:18. doi:10.3389/fneur.2013.00018
22. Balakathiresan N, Bhomia M, Chandran R, Chavko M, McCarron RM, Maheshwari RK. microRNA let-7i is a promising serum biomarker for blast-induced
traumatic brain injury. J Neurotrauma (2012) 29(7):1379–87. doi:10.1089/neu.
2011.2146
23. Terrio H, Brenner LA, Ivins BJ, Cho JM, Helmick K, Schwab K, et al. Traumatic brain injury screening: preliminary findings in a US army brigade
combat team. J Head Trauma Rehabil (2009) 24(1):14–23. doi:10.1097/HTR.
0b013e31819581d8
24. King PR, Donnelly KT, Donnelly JP, Dunnam M, Warner G, Kittleson CJ, et al.
Psychometric study of the neurobehavioral symptom inventory. J Rehabil Res
Dev (2012) 49(6):879–88. doi:10.1682/JRRD.2011.03.0051
25. Wilkins KC, Lang AJ, Norman SB. Synthesis of the psychometric properties of
the PTSD checklist (PCL) military, civilian, and specific versions. Depress Anxiety
(2011) 28(7):596–606. doi:10.1002/da.20837
26. Trivedi MH, Rush AJ, Ibrahim HM, Carmody TJ, Biggs MM, Suppes T, et al.
The inventory of depressive symptomatology, clinician rating (IDS-C) and selfreport (IDS-SR), and the quick inventory of depressive symptomatology, clinician rating (QIDS-C) and self-report (QIDS-SR) in public sector patients with
mood disorders: a psychometric evaluation. Psychol Med (2004) 34(1):73–82.
doi:10.1002/mpr.285
27. MacKenzie EJ, Sacco WJ, Luchter S, Ditunno JF, Staz CF, Gruen GS, et al.
Validating the functional capacity index as a measure of outcome following
blunt multiple trauma. Qual Life Res (2002) 11(8):797–808. doi:10.1023/A:
1020820017658
28. Morris DR, Levenson CW. Zinc in traumatic brain injury: from neuroprotection to neurotoxicity. Curr Opin Clin Nutr Metab Care (2013) 16(6):708–11.
doi:10.1097/MCO.0b013e328364f39c
29. Papa L, Lewis LM, Silvestri S, Falk JL, Giordano P, Brophy GM, et al. Serum levels
of ubiquitin C-terminal hydrolase distinguish mild traumatic brain injury from
trauma controls and are elevated in mild and moderate traumatic brain injury
patients with intracranial lesions and neurosurgical intervention. J Trauma Acute
Care Surg (2012) 72(5):1335–44. doi:10.1097/TA.0b013e3182491e3d
30. Berger RP, Hayes RL, Richichi R, Beers SR, Wang KK. Serum concentrations
of ubiquitin C-terminal hydrolase-L1 and alphaII-spectrin breakdown product 145 kDa correlate with outcome after pediatric TBI. J Neurotrauma (2012)
29(1):162–7. doi:10.1089/neu.2011.1989
31. Diaz-Arrastia R, Wang KK, Papa L, Sorani MD, Yue JK, Puccio AM, et al. Acute
biomarkers of traumatic brain injury: relationship between plasma levels of
ubiquitin C-terminal hydrolase-L1 and glial fibrillary acidic protein. J Neurotrauma (2014) 31(1):19–25. doi:10.1089/neu.2013.3040
32. Kobeissy F, Mondello S, Tümer N, Toklu HZ, Whidden MA, Kirichenko N, et al.
Assessing neuro-systemic & behavioral components in the pathophysiology of
blast-related brain injury. Front Neurol (2013) 4:186. doi:10.3389/fneur.2013.
00186
33. Svetlov SI, Prima V, Glushakova O, Svetlov A, Kirk DR, Gutierrez H, et al. Neuroglial and systemic mechanisms of pathological responses in rat models of primary blast overpressure compared to “composite” blast. Front Neurol (2012)
3:15. doi:10.3389/fneur.2012.00015

October 2014 | Volume 5 | Article 198 | 8

Heinzelmann et al.

34. Svetlov SI, Prima V, Kirk DR, Gutierrez H, Curley KC, Hayes RL, et al.
Morphologic and biochemical characterization of brain injury in a model
of controlled blast overpressure exposure. J Trauma (2010) 69(4):795–804.
doi:10.1097/TA.0b013e3181bbd885
35. Yokobori S, Gajavelli S, Mondello S, Mo-Seaney J, Bramlett HM, Dietrich
WD, et al. Neuroprotective effect of preoperatively induced mild hypothermia as determined by biomarkers and histopathological estimation in a rat
subdural hematoma decompression model. J Neurosurg (2013) 118(2):370–80.
doi:10.3171/2012.10.JNS12725
36. Bilguvar K, Tyagi NK, Ozkara C, Tuysuz B, Bakircioglu M, Choi M, et al. Recessive
loss of function of the neuronal ubiquitin hydrolase UCHL1 leads to early-onset
progressive neurodegeneration. Proc Natl Acad Sci U S A (2013) 110(9):3489–94.
doi:10.1073/pnas.1222732110
37. Sang Q, Kim MH, Kumar S, Bye N, Morganti-Kossman MC, Gunnersen J, et al.
Nedd4-WW domain-binding protein 5 (Ndfip1) is associated with neuronal
survival after acute cortical brain injury. J Neurosci (2006) 26(27):7234–44.
doi:10.1523/JNEUROSCI.1398-06.2006
38. Yao XL, Liu J, Lee E, Ling GS, McCabe JT. Cullin 5 gene expression in the rat cerebral cortex and hippocampus following traumatic brain injury (TBI). Neurosci
Lett (2006) 409(1):65–9. doi:10.1016/j.neulet.2006.09.015
39. Wan C, Chen J, Hu B, Zou H, Li A, Guo A, et al. Downregulation of UBE2Q1 is
associated with neuronal apoptosis in rat brain cortex following traumatic brain
injury. J Neurosci Res (2014) 92(1):1–12. doi:10.1002/jnr.23305
40. Sun KJ, Zhu L, Wang HD, Ji XJ, Pan H, Chen M, et al. Zinc as mediator of ubiquitin conjugation following traumatic brain injury. Brain Res (2013) 1506:132–41.
doi:10.1016/j.brainres.2013.02.011
41. Kotepui M, Thawornkuno C, Chavalitshewinkoon-Petmitr P, Punyarit P, Petmitr
S. Quantitative real-time RT-PCR of ITGA7, SVEP1, TNS1, LPHN3, SEMA3G,
KLB and MMP13 mRNA expression in breast cancer. Asian Pac J Cancer Prev
(2012) 13(11):5879–82. doi:10.7314/APJCP.2012.13.11.5879
42. Ferreira MA, Matheson MC, Tang CS, Granell R, Ang W, Hui J, et al. Genomewide association analysis identifies 11 risk variants associated with the asthma
with hay fever phenotype. J Allergy Clin Immunol (2014) 133(6):1564–71.
doi:10.1016/j.jaci.2013.10.030
43. Chen YH, Keller JJ, Kang JH, Lin HC. Association between traumatic brain injury
and the subsequent risk of brain cancer. J Neurotrauma (2012) 29(7):1328–33.
doi:10.1089/neu.2011.2235
44. Liu B, Neufeld AH. Activation of epidermal growth factor receptors in astrocytes: from development to neural injury. J Neurosci Res (2007) 85(16):3523–9.
doi:10.1002/jnr.21364
45. Liu B, Neufeld AH. Activation of epidermal growth factor receptor causes astrocytes to form cribriform structures. Glia (2004) 46(2):153–68. doi:10.1002/glia.
10358
46. Tado M, Mori T, Fukushima M, Oshima H, Maeda T, Yoshino A, et al. Increased
expression of vascular endothelial growth factor attenuates contusion necrosis without influencing contusion edema after traumatic brain injury in rats.
J Neurotrauma (2014) 31(7):691–8. doi:10.1089/neu.2013.2940
47. Yüksel H, Yavuz Ö, Is M, Çomunoglu N, Üzüm G, Akyüz F, et al. Simvastatin reduces VEGF and NO levels in acute stages of experimental

www.frontiersin.org

Differential gene expression in blast-TBI/PCD

traumatic brain injury. Neurol Sci (2013) 34(11):1941–6. doi:10.1007/s10072013-1411-z
48. Siddiq I, Park E, Liu E, Spratt SK, Surosky R, Lee G, et al. Treatment of traumatic brain injury using zinc-finger protein gene therapy targeting VEGF-A.
J Neurotrauma (2012) 29(17):2647–59. doi:10.1089/neu.2012.2444
49. Hanissian SH, Teng B, Akbar U, Janjetovic Z, Zhou Q, Duntsch C, et al. Regulation of myeloid leukemia factor-1 interacting protein (MLF1IP) expression
in glioblastoma. Brain Res (2005) 1047(1):56–64. doi:10.1016/j.brainres.2005.
04.017
50. Vigodner M, Shrivastava V, Gutstein LE, Schneider J, Nieves E, Goldstein M,
et al. Localization and identification of sumoylated proteins in human sperm:
excessive sumoylation is a marker of defective spermatozoa. Hum Reprod (2013)
28(1):210–23. doi:10.1093/humrep/des317
51. Gill J, Lee H, Barr T, Baxter T, Heinzelmann M, Rak H, et al. Lower health
related quality of life in U.S. military personnel is associated with servicerelated disorders and inflammation. Psychiatry Res (2014) 216(1):116–22.
doi:10.1016/j.psychres.2014.01.046
52. Jerg-Bretzke L, Walter S, Limbrecht-Ecklundt K, Traue HC. Emotional ambivalence and post-traumatic stress disorder (PTSD) in soldiers during military
operations. Psychosoc Med (2013) 10:Doc03. doi:10.3205/psm000093
53. Caldeira MV, Salazar IL, Curcio M, Canzoniero LM, Duarte CB. Role of the
ubiquitin-proteasome system in brain ischemia: friend or foe? Prog Neurobiol
(2014) 112:50–69. doi:10.1016/j.pneurobio.2013.10.003
54. Reynolds JJ, Stewart GS. A nervous predisposition to unrepaired DNA double
strand breaks. DNA Repair (Amst) (2013) 12(8):588–99. doi:10.1016/j.dnarep.
2013.04.011
Conflict of Interest Statement: No author has any conflicts of interest to disclose. The opinions and assertions in this manuscript are those of the authors
and do not necessarily represent those of the Department of the Army, Department
of Defense, U.S. Government, or the Center for Neuroscience and Regenerative
Medicine.
Received: 02 July 2014; accepted: 18 September 2014; published online: 09 October
2014.
Citation: Heinzelmann M, Reddy SY, French LM, Wang D, Lee H, Barr T, Baxter T,
Mysliwiec V and Gill J (2014) Military personnel with chronic symptoms following blast
traumatic brain injury have differential expression of neuronal recovery and epidermal
growth factor receptor genes. Front. Neurol. 5:198. doi: 10.3389/fneur.2014.00198
This article was submitted to Neurotrauma, a section of the journal Frontiers in
Neurology.
Copyright © 2014 Heinzelmann, Reddy, French, Wang , Lee, Barr, Baxter, Mysliwiec
and Gill. This is an open-access article distributed under the terms of the Creative
Commons Attribution License (CC BY). The use, distribution or reproduction in other
forums is permitted, provided the original author(s) or licensor are credited and that
the original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply with
these terms.

October 2014 | Volume 5 | Article 198 | 9

